Incidence of persistent SARS-CoV-2 gut infection in patients with a history of COVID-19: Insights from endoscopic examination

Abstract

Background and study aims Gut infection is common during acute COVID-19, and persistent SARS-CoV-2 gut infection has been reported months after the initial infection, potentially linked to long-COVID syndrome. This study tested the incidence of persistent gut infection in patients with a history of COVID-19 undergoing endoscopic examination.

Patients and methods Endoscopic biopsies were prospectively collected from patients with previous COVID-19 infection undergoing upper or lower gastrointestinal endoscopy (UGE or LGE). Immunohistochemistry was used to detect the presence of persistent SARS-CoV-2 nucleocapsid proteins.

Results A total of 166 UGEs and 83 LGE were analyzed. No significant differences were observed between patients with positive and negative immunostaining regarding the number of previous COVID-19 infections, time since the last infection, symptoms, or vaccination status. The incidence of positive immunostaining was significantly higher in UGE biopsies than in LGE biopsies (37.34% vs. 16.87%, P=0.002). Smokers showed a significantly higher incidence of positive immunostaining in the overall cohort and UGE and LGE subgroups (P <0.001). Diabetic patients exhibited a significantly higher incidence in the overall cohort (P=0.002) and UGE subgroup (P=0.022), with a similar trend observed in the LGE subgroup (P=0.055).

Conclusions Gut mucosal tissues can act as a long-term reservoir for SARS-CoV-2, retaining viral particles for months following the primary COVID-19 infection. Smokers and individuals with diabetes may be at an increased risk of persistent viral gut infection. These findings provide insights into the dynamics of SARS-CoV-2 infection in the gut and have implications for further research.

Keywords

Endoscopy Upper GI Tract - Epidemiology

Publication History

Received: 17 July 2023

Accepted after revision: 21 September 2023

Accepted Manuscript online:
25 September 2023

Article published online:
05 January 2024

• References

• 1 World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19. Accessed January 01, 2000 at: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19
• 2 World Health Organization. Weekly epidemiological update on COVID-19. Accessed January 01, 2000 at: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19
• 3 Vanella G, Capurso G, Burti C. et al. Gastrointestinal mucosal damage in patients with COVID-19 undergoing endoscopy: an international multicentre study. BMJ Open Gastroenterol 2021; 8: e000578
• 4 Brooks EF, Bhatt AS. The gut microbiome: a missing link in understanding the gastrointestinal manifestations of COVID-19?. Cold Spring Harb Mol Case Stud 2021; 7: a006031 DOI: 10.1101/mcs.a006031. (PMID: 33593727)
• 5 Neuberger M, Jungbluth A, Irlbeck M. et al. Duodenal tropism of SARS-CoV-2 and clinical findings in critically ill COVID-19 patients. Infection 2022; 50: 1111-1120 DOI: 10.1007/s15010-022-01769-z. (PMID: 35182354)
• 6 Xiao F, Tang M, Zheng X. et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020; 158: 1831-1833.e3
• 7 Lin L, Jiang X, Zhang Z. et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut 2020; 69: 997-1001
• 8 Martin TA, Wan DW, Hajifathalian K. et al. Gastrointestinal bleeding in patients with coronavirus disease 2019: a matched case-control study. Am J Gastroenterol 2020; 115: 1609-1616
• 9 Cherne MD, Gentry AB, Nemudraia A. et al. Severe acute respiratory syndrome coronavirus 2 is detected in the gastrointestinal tract of asymptomatic endoscopy patients but is unlikely to pose a significant risk to healthcare personnel. Gastro Hep Advances 2022; 1: 844-852 DOI: 10.1016/j.gastha.2022.06.002. (PMID: 35765598)
• 10 Wu Y, Guo C, Tang L. et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol 2020; 5: 434-435 DOI: 10.1016/S2468-1253(20)30083-2. (PMID: 32199469)
• 11 Britton GJ, Chen-Liaw A, Cossarini F. et al. Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19. Sci Rep 2021; 11: 13308
• 12 Zang R, Castro MFG, McCune BT. et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol 2020; 5: eabc3582
• 13 Hany M, Zidan A, Gaballa M. et al. Lingering SARS-CoV-2 in gastric and gallbladder tissues of patients with previous COVID-19 infection undergoing bariatric surgery. Obes Surg 2023; 33: 139-148
• 14 Cheruiyot I, Sehmi P, Ngure B. et al. Laparoscopic surgery during the COVID-19 pandemic: detection of SARS-COV-2 in abdominal tissues, fluids, and surgical smoke. Langenbecks Arch Surg 2021; 406: 1007-1014
• 15 Meringer H, Mehandru S. Gastrointestinal post-acute COVID-19 syndrome. Nat Rev Gastroenterol Hepatol 2022; 19: 345-346 DOI: 10.1038/s41575-022-00611-z. (PMID: 35383321)
• 16 Zollner A, Koch R, Jukic A. et al. Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology 2022; 163: 495-506.e8
• 17 Arostegui D, Castro K, Schwarz S. et al. Persistent SARS-CoV-2 nucleocapsid protein presence in the intestinal epithelium of a pediatric patient 3 months after acute infection. JPGN Reports 2022; 3: e152 DOI: 10.1097/PG9.0000000000000152. (PMID: 37168753)
• 18 Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol 2022; 23: 194-202 DOI: 10.1038/s41590-021-01104-y. (PMID: 35105985)
• 19 Cheung CCL, Goh D, Lim X. et al. Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut 2022; 71: 226-229
• 20 Sandal S, Tanas Ö, Karabulut Ş. et al. A histopathological view at the long-term effects of covid-19 on the gastrointestinal system in children: a single center experience. Turk J Pediatr 2023; 65: 416 DOI: 10.24953/turkjped.2022.1039. (PMID: 37395961)
• 21 Nguyen NN, Mutnal MB, Gomez RR. et al. Correlation of ELISA method with three other automated serological tests for the detection of anti-SARS-CoV-2 antibodies. PLoS One 2020; 15: e0240076
• 22 Gralnek IM, Hassan C, Beilenhoff U. et al. ESGE and ESGENA Position Statement on gastrointestinal endoscopy and the COVID-19 pandemic. Endoscopy 2020; 52: 483-490 DOI: 10.1055/a-1155-6229. (PMID: 32303090)
• 23 Mauro A, De Grazia F, Lenti MV. et al. Upper gastrointestinal bleeding in COVID-19 inpatients: Incidence and management in a multicenter experience from Northern Italy. Clin Res Hepatol Gastroenterol 2021; 45: 101521
• 24 Massironi S, Viganò C, Dioscoridi L. et al. Endoscopic findings in patients infected with 2019 novel coronavirus in Lombardy, Italy. Clin Gastroenterol Hepatol 2020; 18: 2375-2377
• 25 Zhou P, Yang X-L, Wang X-G. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579: 270-273
• 26 Hoffmann M, Kleine-Weber H, Schroeder S. et al. SARS-CoV-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271-280.e8
• 27 Lamers MM, Beumer J, Van Der Vaart J. et al. SARS-CoV-2 productively infects human gut enterocytes. Science 2020; 369: 50-54 DOI: 10.1126/science.abc1669. (PMID: 32358202)
• 28 Zuo T, Zhang F, Lui GCY. et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology 2020; 159: 944-955.e8
• 29 Budden KF, Gellatly SL, Wood DLA. et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol 2017; 15: 55-63
• 30 Mehta P, McAuley DF, Brown M. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033-1034 DOI: 10.1016/S0140-6736(20)30628-0. (PMID: 32192578)
• 31 Carfì A, Bernabei R, Landi F. et al. Persistent symptoms in patients after acute COVID-19. JAMA 2020; 324: 603-605 DOI: 10.1001/jama.2020.12603. (PMID: 32644129)
• 32 Raveendran AV, Misra A. Post COVID-19 syndrome (“Long COVID”) and diabetes: challenges in diagnosis and management: diabetes & metabolic syndrome. Clin Res Rev 2021; 15: 102235
• 33 Fändriks L. The angiotensin II type 2 receptor and the gastrointestinal tract. J Renin Angiotensin Aldosterone Syst 2010; 11: 43-48 DOI: 10.1177/1470320309347788. (PMID: 19861352)
• 34 Lee S, Yoon GY, Myoung J. et al. Robust and persistent SARS-CoV-2 infection in the human intestinal brush border expressing cells. Emerg Microbe Infect 2020; 9: 2169-2179 DOI: 10.1080/22221751.2020.1827985. (PMID: 32969768)
• 35 Jacobs JJL. Persistent SARS-2 infections contribute to long COVID-19. Medical Hypotheses 2021; 149: 110538 DOI: 10.1016/j.mehy.2021.110538. (PMID: 33621843)
• 36 Bai F, Tomasoni D, Falcinella C. et al. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect 2022; 28: 611.e9-611.e16
• 37 Barthélémy H, Mougenot E, Duracinsky M. et al. Smoking increases the risk of post-acute COVID-19syndrome: Results from a French community-based survey. Tob Induc Dis 2022; 20: 1-10
• 38 Su Y, Yuan D, Chen DG. et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 2022; 185: 881-895.e20
• 39 Masiá M, Fernández-González M, Telenti G. et al. Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study. J Autoimmunity 2021; 123: 102703 DOI: 10.1016/j.jaut.2021.102703. (PMID: 34303083)